Cargando…
Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by involvement of skin, axial and peripheral skeleton. An altered balance between extracellular matrix (ECM) formation and breakdown is a key event in PsA, and changes in ECM protein metabolites may provide insight to tissue c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079340/ https://www.ncbi.nlm.nih.gov/pubmed/33885930 http://dx.doi.org/10.1007/s00296-021-04861-z |
_version_ | 1783685207142957056 |
---|---|
author | Holm Nielsen, Signe Sardar, Samra Siebuhr, Anne Sofie Schlemmer, Annette Schmidt, Erik Berg Bay-Jensen, Anne-Christine Karsdal, Morten A. Christensen, Jeppe Hagstrup Kristensen, Salome |
author_facet | Holm Nielsen, Signe Sardar, Samra Siebuhr, Anne Sofie Schlemmer, Annette Schmidt, Erik Berg Bay-Jensen, Anne-Christine Karsdal, Morten A. Christensen, Jeppe Hagstrup Kristensen, Salome |
author_sort | Holm Nielsen, Signe |
collection | PubMed |
description | Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by involvement of skin, axial and peripheral skeleton. An altered balance between extracellular matrix (ECM) formation and breakdown is a key event in PsA, and changes in ECM protein metabolites may provide insight to tissue changes. Dietary fish oils (n-3 PUFA) might affect the inflammation driven tissue turnover. The aim was to evaluate ECM metabolites in patients with PsA compared to healthy individuals and investigate the effects of n-3 PUFA. The 24-week randomized, double-blind, placebo-controlled trial of PUFA included 142 patients with PsA. Fifty-seven healthy individuals were included for comparison. This study is a sub-study investigating biomarkers of tissue remodelling as secondary outcomes. Serum samples at baseline and 24 weeks and healthy individuals were obtained, while a panel of ECM metabolites reflecting bone and soft tissue turnover were measured by ELISAs: PRO-C1, PRO-C3, PRO-C4, C1M, C3M, C4M, CTX-I and Osteocalcin (OC). C1M, PRO-C3, PRO-C4 and C4M was found to be elevated in PsA patients compared to the healthy individuals (from 56 to 792%, all p < 0.0001), where no differences were found for OC, CTX-I, PRO-C1 and C3M. PRO-C3 was increased by 7% in patients receiving n-3 PUFA after 24 weeks compared to baseline levels (p = 0.002). None of the other biomarkers was changed with n-3 PUFA treatment. This indicates that tissue turnover is increased in PsA patients compared to healthy individuals, while n-3 PUFA treatment for 24 weeks did not have an effect on tissue turnover. Trial registration NCT01818804. Registered 27 March 2013–Completed 18 February 2016. https://clinicaltrials.gov/ct2/show/NCT01818804?term=NCT01818804&rank=1 |
format | Online Article Text |
id | pubmed-8079340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80793402021-05-05 Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial Holm Nielsen, Signe Sardar, Samra Siebuhr, Anne Sofie Schlemmer, Annette Schmidt, Erik Berg Bay-Jensen, Anne-Christine Karsdal, Morten A. Christensen, Jeppe Hagstrup Kristensen, Salome Rheumatol Int Clinical Trials Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by involvement of skin, axial and peripheral skeleton. An altered balance between extracellular matrix (ECM) formation and breakdown is a key event in PsA, and changes in ECM protein metabolites may provide insight to tissue changes. Dietary fish oils (n-3 PUFA) might affect the inflammation driven tissue turnover. The aim was to evaluate ECM metabolites in patients with PsA compared to healthy individuals and investigate the effects of n-3 PUFA. The 24-week randomized, double-blind, placebo-controlled trial of PUFA included 142 patients with PsA. Fifty-seven healthy individuals were included for comparison. This study is a sub-study investigating biomarkers of tissue remodelling as secondary outcomes. Serum samples at baseline and 24 weeks and healthy individuals were obtained, while a panel of ECM metabolites reflecting bone and soft tissue turnover were measured by ELISAs: PRO-C1, PRO-C3, PRO-C4, C1M, C3M, C4M, CTX-I and Osteocalcin (OC). C1M, PRO-C3, PRO-C4 and C4M was found to be elevated in PsA patients compared to the healthy individuals (from 56 to 792%, all p < 0.0001), where no differences were found for OC, CTX-I, PRO-C1 and C3M. PRO-C3 was increased by 7% in patients receiving n-3 PUFA after 24 weeks compared to baseline levels (p = 0.002). None of the other biomarkers was changed with n-3 PUFA treatment. This indicates that tissue turnover is increased in PsA patients compared to healthy individuals, while n-3 PUFA treatment for 24 weeks did not have an effect on tissue turnover. Trial registration NCT01818804. Registered 27 March 2013–Completed 18 February 2016. https://clinicaltrials.gov/ct2/show/NCT01818804?term=NCT01818804&rank=1 Springer Berlin Heidelberg 2021-04-22 2021 /pmc/articles/PMC8079340/ /pubmed/33885930 http://dx.doi.org/10.1007/s00296-021-04861-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Trials Holm Nielsen, Signe Sardar, Samra Siebuhr, Anne Sofie Schlemmer, Annette Schmidt, Erik Berg Bay-Jensen, Anne-Christine Karsdal, Morten A. Christensen, Jeppe Hagstrup Kristensen, Salome Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
title | Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
title_full | Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
title_fullStr | Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
title_full_unstemmed | Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
title_short | Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
title_sort | effect of n-3 pufa on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial |
topic | Clinical Trials |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079340/ https://www.ncbi.nlm.nih.gov/pubmed/33885930 http://dx.doi.org/10.1007/s00296-021-04861-z |
work_keys_str_mv | AT holmnielsensigne effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT sardarsamra effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT siebuhrannesofie effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT schlemmerannette effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT schmidterikberg effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT bayjensenannechristine effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT karsdalmortena effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT christensenjeppehagstrup effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial AT kristensensalome effectofn3pufaonextracellularmatrixproteinturnoverinpatientswithpsoriaticarthritisarandomizeddoubleblindplacebocontrolledtrial |